New patient trials surrounding the medication Retatrutide , specifically the 120 milligram formulation branded as ZPHC, indicate a significant effect on body mass reduction and linked chronic illnesses . Experts believe that this combined compound, affecting both GLP-1 and GIP pathways , could o